Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim
Clin Mol Hepatol. 2017;23(4):323-330.   Published online 2017 Sep 5     DOI:
Citations to this article as recorded by Crossref logo
The association of the heterogeneity of HBV reverse transcriptase quasispecies with antiviral efficacy after treatment with nucleos(t)ide analogues for 10 years
Tai-Cheng Zhou, Feng-Wei Liu, Jing-Hua Fan, Si-Hang Zhang, Song-Qin Lv, Zhi-Yong Yu, Yan-Mei Zhang, Liang Zhang, Jia Wei
Infection, Genetics and Evolution.2021; 89: 104706.     CrossRef
Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR
Jingjing Liang, Xinmiao Liang, Hong Ma, Leng Nie, Ying Tian, Guang Chen, Yu Wang
Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
Jolynne Mokaya, Anna L. McNaughton, Phillip A Bester, Dominique Goedhals, Eleanor Barnes, Brian D Marsden, Philippa C. Matthews
Wellcome Open Research.2020; 5: 151.     CrossRef
Current state-of-the-art pharmacotherapy for the management of hepatitis B infection
Hans L. Tillmann, Gbeminiyi Samuel
Expert Opinion on Pharmacotherapy.2019; 20(7): 873.     CrossRef
Reactions Weekly.2018; 1688(1): 98.     CrossRef
Is it possible to predict the development of an entecavir resistance mutation in patients with chronic hepatitis B in clinical practice?
Joon Yeul Nam, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2017; 23(4): 311.     CrossRef